Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Mark S. Cragg"'
Autor:
Geraldine Cambridge, David A. Isenberg, Loren Kell, Samuel J Taylor, Maria J. Leandro, Kavina Shah, Ruth J Pepper, Venkat Reddy, Mark S. Cragg, Scott R. Henderson, Christian Klein
Publikováno v:
Rheumatology. 61:2894-2904
Objectives To investigate key factors that may contribute to the variability of rituximab-mediated peripheral and renal B cell depletion (BCD) in SLE. Methods We analysed: (i) CD19+ B cell counts in patients with SLE before and 1, 2, 3 and 6 months a
Autor:
Florence Lambolez, Margreet Brouwer, Noémie Wald, Sofie Denies, Virginie Rabolli, Romain Pirson, Florence Nyawouame, Diane Jamart, Anne Marie-Cardine, Mathew J. Carter, Julie Preillon, Mark S. Cragg, Julie Déchanet-Merville, Shruthi Prasad, Erica Houthuys, Catherine Hoofd, Lucile Garnero, Vincent Pitard, Martine Bagot, Julia Cuende, Joao Marchante, Angela Pappalardo, Gregory Driessens, Marjorie Mercier, Reece Marillier, Anne-Catherine Michaux, Véronique Baron-Bodo
Publikováno v:
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, 2020, 20 (1), pp.121-131. ⟨10.1158/1535-7163.MCT-20-0464⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2020, 20 (1), pp.121-131. ⟨10.1158/1535-7163.MCT-20-0464⟩
Molecular Cancer Therapeutics, 2020, 20 (1), pp.121-131. ⟨10.1158/1535-7163.MCT-20-0464⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2020, 20 (1), pp.121-131. ⟨10.1158/1535-7163.MCT-20-0464⟩
TIGIT is an immune checkpoint inhibitor expressed by effector CD4 þ and CD8 þ T cells, NK cells, and regulatory T cells (Tregs). Inhibition of TIGIT-ligand binding using antagonistic anti-TIGIT mAbs has shown in vitro potential to restore T-cell fu
Publikováno v:
Biologicals. 69:1-14
Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition with a wide spectrum of disease manifestations and severities, resulting in significant morbidity and mortality. The aetiopathogenesis of SLE is complex. Young women and certa
Autor:
Stephen A. Beers, Yury D. Bogdanov, Khiyam Hussain, Sonya James, Mark S. Cragg, Emma L Sparrow
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 5, p e0251632 (2021)
PLoS ONE, Vol 16, Iss 5, p e0251632 (2021)
Background The major sites for fast synaptic inhibition in the central nervous system (CNS) are ion channels activated by γ-aminobutyric acid (GABA). These receptors are referred as GABA(A) receptors (GABA(A)R). Recent evidence indicates a role of G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6903de3f9f080d0b693080fbb89c50f6
https://eprints.soton.ac.uk/449625/
https://eprints.soton.ac.uk/449625/
Autor:
Claude H.T. Chan, Hannah L Smith, Theodore Sanders, Mark S. Cragg, Vikki English, Björn Frendéus, Martin J. Glennie, Ingrid Teige, Jordana Griffiths, Ruth R. French, Khiyam Hussain, Chris Penfold, Kerry L. Cox, Jane E. Willoughby, Tatyana Inzhelevskaya, Alison L. Tutt, Ian M Mockridge, Monika Semmrich, Jinny Kim, Aymen Al-Shamkhani, Linda Mårtensson
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundPrevious data suggests that anti-OX40 mAb can elicit anti-tumor effects in mice through deletion of Tregs. However, OX40 also has powerful costimulatory effects on T cells which could evoke therapeutic responses. Human trials with anti-OX40
Autor:
Emily R Webb, Sonya James, Tatyana Inzhelevskaya, Alistair Easton, Freja M Sadler, Silvia Lanati, Margaret Ashton-Key, Stephen A. Beers, Carol Wareham, Stuart N. Dunn, Juliet C. Gray, Mark S. Cragg
Publikováno v:
Webb, E R, Lanati, S, Wareham, C, Easton, A, Dunn, S N, Inzhelevskaya, T, Sadler, F M, James, S, Ashton-Key, M, Cragg, M S, Beers, S A & Gray, J C 2020, ' Immune characterization of pre-clinical murine models of neuroblastoma ', Scientific Reports, vol. 10, no. 1, 16695 . https://doi.org/10.1038/s41598-020-73695-9
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-17 (2020)
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-17 (2020)
Immunotherapy offers a potentially less toxic, more tumor-specific treatment for neuroblastoma than conventional cytotoxic therapies. Accurate and reproducible immune competent preclinical models are key to understanding mechanisms of action, interac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7040d338b2c88b82612dd7aba7ac602
https://hdl.handle.net/20.500.11820/f2df8389-6fef-4341-8e68-db28f884b7f7
https://hdl.handle.net/20.500.11820/f2df8389-6fef-4341-8e68-db28f884b7f7
Autor:
John Trowsdale, Ivo Tews, Jianzhu Chen, H.T. Claude Chan, Bjorn Hambe, Justine S. McPartlan, Anne Ljungars, Stephen M. Thirdborough, C. Ian Mockridge, Torbjörn Schiött, Des C. Jones, Ulla-Carin Tornberg, Ali Roghanian, Björn Frendéus, Guangan Hu, Muchaala Yeboah, Mikael Mattsson, Charys Papagregoriou, Ulrika Mattson, Martin J. Glennie, Mark S. Cragg
Publikováno v:
JCI Insight, Vol 5, Iss 18 (2020)
JCI Insight
JCI Insight
Despite advances in identifying the key immunoregulatory roles of many of the human leukocyte immunoglobulin-like receptor (LILR) family members, the function of the inhibitory molecule LILRB3 (ILT5, CD85a, LIR3) remains unclear. Studies indicate a p
Autor:
Jianzhu Chen, Des C. Jones, Torbjörn Schiött, Stephen M. Thirdborough, Ulla-Carin Tornberg, Bjorn Hambe, H.T. Claude Chan, Martin J. Glennie, Anne Ljungars, Muchaala Yeboah, Mikael Mattsson, Björn Frendéus, John Trowsdale, Ivo Tews, Justine S. McPartlan, Mark S. Cragg, Guangan Hu, Charys Papagregoriou, Ulrika Mattson, C. Ian Mockridge, Ali Roghanian
Despite advances in identifying the key immunoregulatory roles of many of the human leukocyte immunoglobulin (Ig)-like receptor (LILR) family members, the function of the inhibitory molecule LILRB3 (ILT5, CD85a, LIR3) remains unclear. Studies indicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94c0c7323002fa1751cf70f54bb29002
https://doi.org/10.1101/2020.06.04.135400
https://doi.org/10.1101/2020.06.04.135400
Autor:
Paolo Cravedi, Clara R. Farley, Mark S. Cragg, Anna B. Morris, David F. Pinelli, Christopher D. Scharer, Layne E. Adams, Miguel Fribourg, Jeremy M. Boss, Mandy L. Ford, Peter S. Heeger
Effector CD8+ T cells are important mediators of adaptive immunity, and receptor-ligand interactions that regulate their survival may have therapeutic potential. Here, we identified a subset of effector CD8+ T cells that expressed the inhibitory frag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f883b2a890042dd5b19c0f8850e2c7ba
https://eprints.soton.ac.uk/437211/
https://eprints.soton.ac.uk/437211/
Autor:
Jianzhu Chen, Matthew J. Meyer, Heather Huet, Margaret Ashton-Key, Russell Foxall, Stephen A. Beers, Stephen M. Thirdborough, Emma Lees, Guangan Hu, Ali Roghanian, Christopher Fraser, Mark S. Cragg, Sean H. Lim, Maneesh Singh, Martin J. Glennie
Publikováno v:
Cancer Immunol Res
Therapy-resistant microenvironments represent a major barrier toward effective elimination of disseminated cancer. Many hematologic and solid tumors are resistant to therapeutic antibodies in the bone marrow (BM), but not in the periphery (e.g., sple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe73a0758b6fc9f363ed50fe942210e0
https://eprints.soton.ac.uk/434735/
https://eprints.soton.ac.uk/434735/